pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NEUROCRINE · news · pharmadog
← back to NEUROCRINE
News mentioning NEUROCRINE
23
stories
1d
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
1d
STAT+: One of the most consequential years for cancer treatment, ever
stat
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
3d
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
stat
3d
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
stat
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
7d
STAT+: Commure terminates payments under its customer referral programs tied to AI products
stat
7d
STAT+: Eli Lilly targets booming black market for retatrutide
stat
8d
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
stat
8d
Four questions on new safety warnings for Neurocrine’s Vykat XR
endpoints
8d
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
biospace
8d
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
stat
8d
STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
stat
9d
STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
stat
9d
STAT+: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care
stat
9d
STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
stat
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
17d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
20d
Novo setback casts doubt on a new way to treat heart disease
biopharma dive
28d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 7, 26
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
biopharma dive
May 15, 26
FDA hold puts Aardvark Prader-Willi drug in limbo
biopharma dive
